Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 72956-09-3
Drug Levels and Effects
Summary of Use during Lactation
No published information is available on the use of carvedilol during breastfeeding. Based on its physicochemical properties, carvedilol appears to present a low-risk to the breastfed infant. Because there is no published experience with carvedilol during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
The excretion of beta-adrenergic blocking drugs into breastmilk is largely determined by their protein binding. Those with low binding are more extensively excreted into breastmilk.[1] Accumulation of the drugs in the infant is related to the fraction excreted in urine. With 95% protein binding, 1% renal excretion and a moderately long half-life, carvedilol presents a low risk for accumulation in infants.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A study of mothers taking beta-blockers during nursing found a numerically, but not statistically significant increased number of adverse reactions in those taking any beta-blocker. Although the ages of infants were matched to control infants, the ages of the affected infants were not stated. None of the mothers were taking carvedilol.[2]
Effects on Lactation and Breastmilk
Relevant published information on the effects of beta-blockade or carvedilol during normal lactation was not found as of the revision date. A study in 6 patients with hyperprolactinemia and galactorrhea found no changes in serum prolactin levels following beta-adrenergic blockade with propranolol.[3]
Alternate Drugs to Consider
References
- 1.
- Riant P, Urien S, Albengres E, et al. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol 1986;35:4579-81. [PubMed: 2878668]
- 2.
- Ho TK, Moretti ME, Schaeffer JK, et al. Maternal beta-blocker usage and breast feeding in the neonate. Pediatr Res 1999;45 (4, pt. 2):67A. doi:10.1203/00006450-199904020-00402 [CrossRef]
- 3.
- Board JA, Fierro RJ, Wasserman AJ, et al. Effects of alpha- and beta-adrenergic blocking agents on serum prolactin levels in women with hyperprolactinemia and galactorrhea. Am J Obstet Gynecol 1977;127:285-7. [PubMed: 556882]
Substance Identification
Substance Name
Carvedilol
CAS Registry Number
72956-09-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Antihypertensive Agents
Adrenergic Beta-Antagonists
Antiarrhythmics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol.[Molecular Imaging and Contrast...]Review 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol.Leung K. Molecular Imaging and Contrast Agent Database (MICAD). 2004
- Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy)ethylamino)propan-2-ol analogs and its enantiomers. Part 2.[Eur J Med Chem. 2009]Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy)ethylamino)propan-2-ol analogs and its enantiomers. Part 2.Groszek G, Nowak-Król A, Wdowik T, Swierczyński D, Bednarski M, Otto M, Walczak M, Filipek B. Eur J Med Chem. 2009 Dec; 44(12):5103-11. Epub 2009 Jul 21.
- Review Carvedilol.[Profiles Drug Subst Excip Rela...]Review Carvedilol.Beattie K, Phadke G, Novakovic J. Profiles Drug Subst Excip Relat Methodol. 2013; 38:113-57.
- 1-(9H-Carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol hemihydrate: a carvedilol solvatomorph.[Acta Crystallogr C. 2011]1-(9H-Carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol hemihydrate: a carvedilol solvatomorph.Díaz F, Benassi A, Quintero M, Polla G, Freire E, Baggio R. Acta Crystallogr C. 2011 Jul; 67(Pt 7):o222-5. Epub 2011 Jun 4.
- Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations.[J Pharm Sci. 2012]Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations.Zielińska-Pisklak M, Pisklak DM, Wawer I. J Pharm Sci. 2012 May; 101(5):1763-72. Epub 2012 Feb 13.
- Carvedilol - Drugs and Lactation Database (LactMed®)Carvedilol - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...